Estados Unidos · Agencias y tiempo real · PR Newswire

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

Publicado por PR Newswire · Estados Unidos hace 1 h

SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative…

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

También te puede interesar

Chamberlain University Opens First Utah Campus and 26th Location Nationwide, Expanding Nursing Education in the State with the Fewest Nurses per Capita

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

Compartir

También te puede interesar

Chamberlain University Opens First Utah Campus and 26th Location Nationwide, Expanding Nursing Education in the State with the Fewest Nurses per Capita

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows